A new paper published in Lupus Science & Medicine on the results of a study in China reported that a potential treatment telitacicept demonstrated favorable effectiveness and safety in patients with active SLE. It also improved effects of lupus on kidneys and the blood.

Telitacicept is conditionally approved in China as a treatment for active SLE since 2021.

In this 24-week multicenter Phase 2b study, 72 patients received telitacicept for at least 24 weeks in China. Of these, 21 received treatment with telitacicept for 52 weeks. At 52 weeks, 80.95% of patients achieved the status of Lupus Low Disease Activity and 23.81% achieved disease remission.

Click for More Study Details